Removing comfort pads between babies in neonatal intensive care beds and image detectors reduces the radiation exposure amount to the baby.
Comfort pads placed beneath babies in neonatal intensive care beds should be removed prior to radiography to reduce radiation exposure to the patient, according to a study published in the journal Academic Radiology.
Researchers from Riley Hospital for Children, Indiana University Health in Indianapolis, undertook a study to assess the potential of reducing the exposure index (EI) standard if the comfort pad was removed. Generally, the pad is kept between the baby and the image detector plate, which allows it to absorb some of the x-rays.
The researchers used a phantom to simulate imaging of a baby weighing 1,500 grams along with four thicknesses of comfort pads: 0.5, 1, 3, and 8 inches. They measured the percentage of radiation that was absorbed by the pads.
The results showed that radiation beam attenuation ranged from 12 percent to 72.1 percent, depending on the pad thickness: 0.5-inch pad: 12 percent; 1-inch pad: 27 percent; 3-inch pad: 42.4 percent; and 8-inch pad: 72.1 percent.
The researchers concluded that the comfort pads caused high attenuation of the radiation beam and they presented their findings to the unit administrators. This resulted in a new policy that called for removal of the pads during radiography.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.